NASDAQ:ADMA

ADMA Biologics (ADMA) Stock Price, News & Analysis

ADMA Biologics logo
$14.04 +0.41 (+2.97%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About ADMA Biologics Stock (NASDAQ:ADMA)

Advanced

Key Stats

Today's Range
$13.57
▼
$14.20
50-Day Range
$8.61
▼
$13.68
52-Week Range
$7.21
▼
$20.46
Volume
1.36 million shs
Average Volume
4.14 million shs
Market Capitalization
$3.11 billion
P/E Ratio
18.23
Dividend Yield
N/A
Price Target
$17.50
Consensus Rating
Moderate Buy

Company Overview

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings.

The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida. Its products are marketed in the United States.

Founded in 2004, ADMA has focused on expanding access to plasma-derived treatments. Adam Grossman, a company co-founder, has served as its chief executive officer.

AI Generated. May Contain Errors.

ADMA Biologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

ADMA MarketRank™: 
4.024926686215 of 5 stars

ADMA Biologics scored higher than 80% of companies evaluated by MarketBeat, and ranked 79th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ADMA Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    ADMA Biologics has a consensus price target of $17.50, representing about 28.4% upside from its current price of $13.63.

  • Amount of Analyst Coverage

    ADMA Biologics has only been the subject of 3 research reports in the past 90 days.

  • Read more about ADMA Biologics' stock forecast and price target.
  • Earnings Growth

    Earnings for ADMA Biologics are expected to grow by 4.88% in the coming year, from $0.82 to $0.86 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ADMA Biologics is 17.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.24.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ADMA Biologics is 17.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.97.

  • Price to Book Value per Share Ratio

    ADMA Biologics has a P/B Ratio of 6.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.38% of the float of ADMA Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    ADMA Biologics has a short interest ratio ("days to cover") of 7.11.
  • Change versus previous month

    Short interest in ADMA Biologics has recently decreased by 7.65%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ADMA Biologics does not currently pay a dividend.

  • Dividend Growth

    ADMA Biologics does not have a long track record of dividend growth.

  • News Sentiment

    ADMA Biologics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for ADMA Biologics this week, compared to 8 articles on an average week.
  • Search Interest

    23 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 229% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $139,200.00 in company stock.

  • Percentage Held by Insiders

    3.90% of the stock of ADMA Biologics is held by insiders.

  • Percentage Held by Institutions

    75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ADMA Biologics' insider trading history.
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADMA Stock News Headlines

ADMA Biologics (NASDAQ:ADMA) Director Sells $139,200.00 in Stock
ADMA Biologics Earnings Call Signals Stronger Growth
Gold Trades Near Record Highs: What It Means for Miners
Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold. Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program. With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district.tc pixel
ADMA Biologics: Ending 2026 On A High Note
ADMA Biologics (NASDAQ:ADMA) Price Target Raised to $13.00
See More Headlines

ADMA Stock Analysis - Frequently Asked Questions

ADMA Biologics' stock was trading at $18.24 at the start of the year. Since then, ADMA stock has decreased by 25.3% and is now trading at $13.63.

ADMA Biologics Inc (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, November, 4th. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.20 by $0.03. The business's revenue for the quarter was up 5.1% compared to the same quarter last year.
Read the conference call transcript
.

ADMA Biologics (ADMA) raised $30 million in an initial public offering (IPO) on the week of November 10th 2014. The company issued 3,352,941 shares at $8.50-$9.50 per share.

ADMA Biologics' top institutional investors include State Street Corp (6.11%), First Trust Advisors LP (4.48%), Goldman Sachs Group Inc. (1.27%) and Nantahala Capital Management LLC (1.16%). Insiders that own company stock include Adam S Grossman, Steve Elms, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade and Lawrence P Guiheen.
View institutional ownership trends
.

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Ford Motor (F), Micron Technology (MU) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
11/04/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ADMA
CIK
1368514
Employees
647
Year Founded
2004

Price Target and Rating

High Price Target
$21.00
Low Price Target
$13.00
Potential Upside/Downside
+25.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.77
Trailing P/E Ratio
18.15
Forward P/E Ratio
16.25
P/E Growth
N/A
Net Income
$146.93 million
Net Margins
35.14%
Pretax Margin
45.18%
Return on Equity
42.56%
Return on Assets
26.96%

Debt

Debt-to-Equity Ratio
0.45
Current Ratio
6.04
Quick Ratio
3.25

Sales & Book Value

Annual Sales
$510.17 million
Price / Sales
6.08
Cash Flow
$0.68 per share
Price / Cash Flow
20.59
Book Value
$1.98 per share
Price / Book
7.06

Miscellaneous

Outstanding Shares
221,850,000
Free Float
213,202,000
Market Cap
$3.10 billion
Optionable
Optionable
Beta
0.65

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:ADMA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners